You can narrow down the results using the filters
-
Effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) on urinary glucose excretion in type 2 diabetes
Expand descriptionGlucose-dependent insulinotropic polypeptide (GIP) is a natural hormone released from the intestines after meals. It regulates blood sugar levels by controlling insulin secretion. Our recent studies suggest it may also regulate glucose excretion in the urine. We want to find out whether giving an intravenous infusion of GIP can affect urinary glucose excretion in people with type 2 diabetes.
-
IDEAL Care: Identifying Advanced Liver Fibrosis in Primary Care
Expand descriptionThis study aims to assess the effectiveness, cost-effectiveness, and implementation context of an integrated liver fibrosis detection pathway in detecting unrecognized advanced liver fibrosis in at-risk patients in primary care. Who is it for? You may be eligible to participate in this trial if you are between 45-75 years and are at risk of chronic liver disease and are under the care of a GP at a participating general practice clinic, Study details GP clinics will be randomised to one of two cluster groups. One group will receive usual care provided by their GP. The other group will have a liver fibrosis detection pathway implemented through the Future Health Today (FHT) clinical decision support system (CDSS). GPs will be alerted by the CDSS from the electronic patient medical record if their patient is at-risk for advanced liver fibrosis and warrant further investigation. Further investigation will be prompted by way of a screening blood test for liver fibrosis and then a diagnostic special liver ultrasound, known as a liver elastogram. It is hoped that this research will demonstrate if this clinical decision support system is effective in improving detection of liver disease and liver cancer, thus improving patient outcomes.
-
Targeting wellBeing in AdoLescent and young Adult treated for CaNCEr (BALANCE)
Expand descriptionThis study evaluates a lifestyle program that aims to improve quality of life in young people who are recovering from cancer treatment. Who is it for? You are eligible for this study if you are aged between 15-25 years of age and have either completed intensive treatment (surgery, chemotherapy and radiotherapy) or are on maintenance therapy for any cancer diagnosis. Study details Participants will receive access to online lifestyle modules to work through over eight weeks, as well as three individual one-hour consultations with Canteen staff (cancer nurses, psychologists and social workers) to discuss how to identify and meet their wellbeing needs. Participants will also be asked to complete questionnaires on their physical and mental health status. It is hoped that findings from this study will help develop programs to ensure young people who survive cancer have the same quality of life as young people who haven’t had cancer.
-
Nasal high-flow during deferred cord clamping in very preterm infants
Expand descriptionDeferred (delayed) cord clamping for at least 60 seconds improves survival in very preterm infants. However, some infants require positive pressure ventilation to establish breathing in the first minutes after birth. For these infants, the cord is often clamped early, therefore they miss out on the benefits of deferred cord clamping. Furthermore, positive pressure ventilation may injure the fragile preterm lung. Nasal high-flow therapy (nasal high-flow) provides heated, humidified, blended air and oxygen via two small nasal prongs. We hypothesise that the provision of nasal high-flow prior to cord clamping may support and stimulate breathing, therefore allowing deferred cord clamping to occur and limiting positive pressure ventilation, improving outcomes. In this single-centre pilot feasibility trial, preterm infants born 26-31+6 weeks’ gestation will receive nasal high-flow during deferred cord clamping. We aim to study the feasibility of providing nasal high-flow prior to cord clamping in 20 infants with respect to 1) acceptability to clinicians and 2) practical application. We will also study clinical and physiological outcomes in infants receiving nasal high-flow during deferred cord clamping. These pilot data will help establish feasibility for a larger randomised controlled trial, and inform the primary outcome and sample size for this definitive trial.
-
A randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of SAR446422 in healthy, adult participants
Expand descriptionThis is a randomized, placebo-controlled, sequential, participant- and Investigator-masked Phase 1 study to assess the safety, tolerability, PK, and PD of ascending single and multiple doses of SAR446422 in female and male healthy participants 18 to 55 years of age. Number of participants: Up to 120 participants will be randomized to study intervention at a single study site. Part1-SAD17875: approximately 9 dose level cohorts with 8 participants per cohort (6 active and 2 placebo). The last cohort will be optional. Part2-MAD17876: approximately 4 dose level cohorts with 12 participants per cohort (9 active and 3 placebo). The last cohort will be optional.
-
Assessing cardiovascular disease risk from retinal images using artificial intelligence at primary care settings
Expand descriptionResearchers at the Centre for Eye Research Australia (CERA) in collaboration with industry partner Eyetelligence Pty Ltd have developed a system integrating retinal photography and artificial intelligence (AI) to predict the risk of heart diseases. The retina is located at the back of the eye and has the important ability to sense vision. When the retina is photographed, it shows small vessels that can indicate the health of your heart. The cardiovascular disease (CVD) risk score refers to the probability of developing CVD events in the future. This project aims to assess the real-world impact, accuracy, and feasibility of the rpCVD screening system in primary care settings in Australia.
-
Maintaining Social Engagement: A social cognitive skills intervention for older adults with cognitive concerns.
Expand descriptionOlder adults with cognitive concerns are at greater risk of loneliness, depression, and dementia. Often their cognitive difficulties are related not only to memory problems, but also to problems interacting and engaging socially with others. These problems include misreading body language, missing social cues, and having difficulty keeping conversations going. Existing treatments focus on improving memory or language, but there is no treatment that helps people enhance or maintain their social skills and connections. We received a Dementia Australia pilot grant in 2020 to co-design a ‘Maintaining Social Engagement program’ with Dementia Australia advocates. We successfully piloted this program with 10 people and found improvements in social cognitive skills (understanding oneself, understanding others, communicating with others). A randomised controlled trial will test if the program helps older adults with cognitive concerns to stay socially connected, feel more confident in social situations, and contribute to activities that are meaningful for them and potentially improve their quality of life.
-
HYPO-BL: Breast Lymphoedema and Radiation Treatment Randomised Controlled Trial – Ultra versus Moderate Breast Hypofractionation Radiation Treatment
Expand descriptionThis study aims to determine the incidence of breast oedema following whole breast radiotherapy using an objective measure of TDC measurements, to determine the difference, if any, between a moderately hypofractionated radiation schedule and an accelerated ultra-hypofractionated schedule. Who is it for? You may be eligible for this study if you are a woman aged 50 years or older and have been diagnosed with breast cancer. Study details Participants will be randomised to one of two possible treatments: the current standard of care of "moderate hypofractionation" treatment, as 40.05 Gy in 15 fractions as daily treatment sessions for 15-19 consecutive days; or " ultra-hypofractionation" treatment, as 26 Gy in 5 fractions to the whole breast, delivered in 5 sessions over 5-9 days. A tumour bed boost is an optional component of both treatments. Participants will be followed for 60 months after the treatment to determine post-radiotherapy breast changes, such as swelling and oedema, quality of life and other patient reported outcomes. It is hoped that this research will help to improve the safety, patient experience, and efficacy of breast cancer treatment.
-
DExmedetomidine in Cardiac surgical Intraoperative Drug Evaluation
Expand descriptionDelirium (confusion) is a common complication of cardiac surgery. Dexmedetomidine, a routinely used sedative, has been shown to reduce delirium in different populations. This study aims to test if dexmedetomidine can reduce delirium after surgery in patients undergoing cardiac surgery aged 65 years or older. The aim of the study is to see whether a medication called dexmedetomidine (a routinely used sedative) impacts delirium after surgery. We hypothesize that dexmedetomidine will reduce delirium after surgery.
-
A study comparing two different handpieces for dental plaque removal with an air polishing device
Expand descriptionClinical, microbiological and histological studies have confirmed the safety and efficacy of air polishing devices with the use of glycine and erythritol powder for the removal of biofilm in prophylaxis and in the treatment of periodontitis and peri-implantitis (Petersilka, 2011). There appears to be minimal scientifically validated or published data in the current literature base pertaining to the novel Airflow® MAX handpiece. This study is intended to provide an initial investigation regarding the the efficacy, safety, patient reported outcomes and aerosol generation of an air polishing device used in dentistry in conjunction with a novel EMS Airflow® MAX handpiece as compared to the conventional EMS Airflow® handpiece. The hypothesis is that the EMS Airflow® MAX handpiece is as safe and efficacious as the conventional EMS Airflow® handpiece in professional prophylaxis (biofilm and stain removal).